PRTG News and Press, Portage Biotech Inc. From 08/18/22

CEO Dr. Ian Walters to take on additional responsibility as Chairman of the Board Justin Fairchild, MPH, an expert in clinical immunotherapy, appointed Vice President of Development WESTPORT, Conn., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a c...

--Company Continues to Execute on Core Business Model While Enhancing Value Proposition and Pipeline with Recent Transactions-- --Robust Pipeline Now Includes Four Fully Owned, Clinical-Stage Assets-- --Cash Runway for New and Current Programs Potentially Extended into 2...

--Company Continues to Execute on Core Business Model While Enhancing Value Proposition and Pipeline with Recent Transactions-- --Robust Pipeline Now Includes Four Fully Owned, Clinical-Stage Assets-- --Cash Runway for New and Current Programs Potentially Extended into 2...

Portage Biotech ( NASDAQ: PRTG ) stock has added 16.8% to $10.95 in Wednesday morning trading, after the company said it had acquired the remaining ownership interest in its invariant natural killer T cell (iNKT cell) agonist platform. iNKT cells play an important ...

WESTPORT, Conn., July 20, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today announced that the Company has a...

Portage Biotech ( NASDAQ: PRTG ) on Wednesday said it would acquire privately-held Tarus Therapeutics in exchange for about 2.4M PRTG shares and the assumption of $3M in liabilities. The acquisition of Tarus allows PRTG to acquire two clinical-stage adenosine compounds...

Acquires two clinical-stage, best in class adenosine compounds, and two preclinical assets for approximately $21 million upfront consideration Rob Glassman, M.D., Ph.D., director of Tarus and former Venture partner at OrbiMed, to join the Portage Board of Directors Enter...

WESTPORT, Conn., June 06, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today announced that the Company prese...

Collaboration will advance preclinical and potential clinical development of STING agonists and anti-RAGE agents for cancer vaccines Portage and NCI will develop agents to enhance the efficacy of proprietary cancer vaccines and mouse model cancer vaccines developed by the NCI ...

WESTPORT, Conn., April 13, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc., (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer t...